Universitaetsklinikum Carl Gustav Carus TU Dresden

Dresden, Saxony 1307

2 studies enrolling now · 14 studies all time

What they study most

Alzheimer's Disease, Atypical Parkinsonism, Branch Retinal Vein Occlusion, Carcinoma, Merkel Cell, Central Retinal Vein Occlusion, Chronic Cutaneous Lupus Erythematosus, Coagulation Disorder, Diabetic Macular Edema, Endometrial Neoplasms, Gastric Adenocarcinoma, Hemi-retinal Vein Occlusion, Hemophilia A

Studies at this site

• Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) — Recruiting now
• A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery — Recruiting now
• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus — Running, not enrolling
• A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products — Running, not enrolling
• A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 — Completed
• AMX0035 and Progressive Supranuclear Palsy — Completed
• Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia — Stopped early
• A Study of BAX 888 in Male Adults With Severe Hemophilia A — Completed
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors — Completed
• Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma — Stopped early
• Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200) — Completed
• A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer — Completed
• A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis — Completed